[5] [16] The cardiovascular and metabolic benefits of significant weight loss achieved with Zepbound may outweigh theoretical cancer concerns for many patients
Estimated mean change in body weight from baseline to week 64 was 13.6% with oral semaglutide 25 mg versus 2.2% with placebo, an estimated difference of 11.4 percentage points
The Science vs Marketing of Stable BPC 157 Marketing tactics have significantly swayed the narrative shaping Stable BPC 157, potentially eclipsing an unbiased scientific evaluation
An Arizona Mailbox Becomes an Oven Several years ago, a retired professor of molecular biology decided to conduct his own experiment
GLP-1 receptor agonists and breast cancer: metabolic insights and clinical implications
Mancuso C, Bates TE, Butterfield DA, Calafato S, Cornelius C, De Lorenzo A, Dinkova Kostova AT, Calabrese V: Natural antioxidants in Alzheimer's disease